Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05344170




Registration number
NCT05344170
Ethics application status
Date submitted
12/04/2022
Date registered
25/04/2022
Date last updated
6/02/2024

Titles & IDs
Public title
Cannabinol Use in Patients With Insomnia Disorder
Scientific title
A Randomised, Double-blind, Placebo-controlled, Single-dose, Crossover, Pilot Study Investigating the Effects of Cannabinol (CBN) 30 mg and 300 mg on Sleep Architecture and Next-day Function in Insomnia Disorder
Secondary ID [1] 0 0
112/2021-08-907
Universal Trial Number (UTN)
Trial acronym
CUPID
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Insomnia Disorder 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 30 mg Cannabinol (CBN)
Treatment: Drugs - 300 mg Cannabinol (CBN)
Treatment: Drugs - Placebo

Experimental: 30 mg Cannabinol (CBN) - Single fixed dose administered 2 hours prior to habitual sleep onset.

Experimental: 300 mg Cannabinol (CBN) - Single fixed dose administered 2 hours prior to habitual sleep onset.

Placebo Comparator: Placebo - Single fixed dose administered 2 hours prior to habitual sleep onset.


Treatment: Drugs: 30 mg Cannabinol (CBN)
Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.

Treatment: Drugs: 300 mg Cannabinol (CBN)
Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.

Treatment: Drugs: Placebo
Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Wake After Sleep Onset (WASO)
Timepoint [1] 0 0
Night 1
Secondary outcome [1] 0 0
Traditional sleep staging
Timepoint [1] 0 0
Night 1
Secondary outcome [2] 0 0
Sleep Onset Latency (SOL)
Timepoint [2] 0 0
Night 1
Secondary outcome [3] 0 0
Absolute Electroencephalographic (EEG) Power During Non-Rapid Eye Movement (NREM) Sleep.
Timepoint [3] 0 0
Night 1

Eligibility
Key inclusion criteria
1. Between 25 - 65 years of age

2. Insomnia Severity Index (ISI) score = 15 at eligibility screening

3. Insomnia disorder (symptoms occurring at least 3 times per week and present for longer
than 3 months) as determined by the study physician

4. Ability to take oral medication

5. Provision of signed and dated informed consent form

6. Stated willingness to comply with all study procedures and availability for the
duration of the study
Minimum age
25 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Medical condition or medication that is the cause of the insomnia disorder as
determined by the study physician

2. Known hypersensitivity to cannabis or cannabinoid products (including if this becomes
evident during the trial)

3. Reported use of cannabis or cannabinoid products within the past 3 months as confirmed
by at least one negative urine drug screen (UDS) (or at the study physician's
discretion)

4. Sleep apnoea (defined as Apnoea Hypopnea Index [AHI] > 15 and Oxygen Desaturation
Index [ODI]>10) as confirmed by polysomnography at screening

5. Sleep-related movement disorder as determined by the study physician

6. Delayed or advanced sleep phase syndrome (based on actigraphy and sleep diary) as
confirmed during screening

7. Any medical condition that produces an abnormal EEG (i.e., epilepsy, brain injury)

8. Clinically relevant cardiovascular abnormalities as determined by the study physician
and a 12-lead electrocardiogram (ECG) at screening

9. Shift work or trans meridian travel (two time zones) within the last month

10. History of major psychiatric disorder in the past 12 months at the study physician's
discretion, except clinically managed mild depression and/or anxiety

11. History of suicide attempt or current suicide ideation (score greater than 1 on Q9 of
the Patient Health Questionnaire [PHQ-9])

12. Pregnancy or lactating. Female participants are required to complete a urine pregnancy
test at screening and treatment sessions and all participants are instructed to use a
reliable form of contraception throughout the study duration

13. History of drug or alcohol dependency or abuse within approximately the past 2 years

14. Use of CNS-active drugs (cannabis, amphetamines, cocaine, antidepressants, opioids,
benzodiazepines) in the past 3 months as confirmed by a positive urine drug test at
screening or at the study physician's discretion

15. Use of medications that may have a clinically significant impact upon the metabolism
and excretion of cannabinoids as determined by the study physician (e.g., CYP450
enzyme inducers/inhibitors

16. Excessive caffeine use that in the opinion of the study physician contributes to the
participant's insomnia disorder, or the inability to abstain from caffeine use 24
hours prior to each overnight sleep study

17. Inability to refrain from alcohol consumption 24 hours prior to each overnight sleep
study

18. Individuals with nicotine dependence (i.e., daily smokers)

19. Medical conditions that result in frequent need to get out of bed (e.g., sleep
walking, nocturia)

20. Psychological or behavioural treatment for insomnia disorder, including cognitive
behavioural therapy for insomnia, within 3 months before screening (excluding sleep
hygiene advice)

21. Occupational or judicially ordered drug screening

22. Has held an unrestricted driving license < 1 year

23. Cannot speak English fluently

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/09/2023
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Woolcock Institute of Medical Research - Glebe
Recruitment postcode(s) [1] 0 0
2095 - Glebe

Funding & Sponsors
Primary sponsor type
Other
Name
Woolcock Institute of Medical Research
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
University of Sydney
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus
placebo, on sleep architecture and next-day functioning in adults aged 25-65 years with
chronic insomnia disorder.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05344170
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Camilla Hoyos, MPH, PhD
Address 0 0
Woolcock Institute of Medical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries